Kent u de chatbox al? chat met andere beleggers


Pfizer

Beleggen in aandelen beurs New York, Dow Jones, Nasdaq-100 en S&P500

Gebruikersavatar
Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1533
Lid geworden op: 17 sep 2014 14:20
waarderingen: 649
Contacteer:

Re: Pfizer

Bericht door Munnybunny »

Gaat $39 neerhalen.





Volg Beursig.com op Twitter en Facebook

     


Gebruikersavatar
BioCocktail
Forum verkenner
Forum verkenner
Berichten: 72
Lid geworden op: 01 jul 2020 15:31
waarderingen: 21
Contacteer:

Re: Pfizer

Bericht door BioCocktail »

Munnybunny schreef:
21 aug 2020 20:43
Gaat $39 neerhalen.
Dat denk ik wel. Downside is beperkt tov upside. Goede covid-play voor aandeel dat m.i. al ondergewaardeerd was. Afhankelijk van bio- en algemeen (VS) beursklimaat zie ik 45$ voor jaareinde. We zien wel.

Gebruikersavatar
BioCocktail
Forum verkenner
Forum verkenner
Berichten: 72
Lid geworden op: 01 jul 2020 15:31
waarderingen: 21
Contacteer:

Re: Pfizer

Bericht door BioCocktail »

https://www.fool.com/amp/investing/2020 ... ve-a-coro/
In July, Pfizer and BioNTech signed a deal with the U.S. government to supply 100 million doses of BNT162b2 for $1.95 billion. That agreement could be expanded in the future for the U.S. to buy up to 500 million additional doses. But receipt of any of this money hinges on FDA authorization or approval of BNT162b2.

Pfizer's shares are in negative territory year to date despite investors' excitement about its COVID-19 program. The recent decision to replace the pharma stock on the Dow Jones Industrial Average didn't help matters. Pfizer could use a major positive catalyst. A win for its coronavirus vaccine in October would likely do the trick.

Gebruikersavatar
BioCocktail
Forum verkenner
Forum verkenner
Berichten: 72
Lid geworden op: 01 jul 2020 15:31
waarderingen: 21
Contacteer:

Re: Pfizer

Bericht door BioCocktail »


Gebruikersavatar
Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1533
Lid geworden op: 17 sep 2014 14:20
waarderingen: 649
Contacteer:

Re: Pfizer

Bericht door Munnybunny »

Here’s Why You Should Be Buying Pfizer Like Its Insiders

Wall Street deal maker Ronald E. Blaylock has just made his first investment in Pfizer PFE +0.1% stock three years after he joined the board — signalling there is about to be an upward move in the company’s fortunes.

The Corporate Governance insider, who sits on the Audit Committee, snapped up $500k shares just three weeks ago ahead of the hotly anticipated Q4 $195bn Mylan MYL +0.3% and Upjohn mega-merger-Spinoff called Viatris — as well as the Cerevel Therapeutics Nasdaq NDAQ 0.0% IPO.

A Pfizer director since 2017, Mr Blaylock, 60, founded top US investment banking firm Blaylock & Company, later the private equity firm GenNx360, and originally served on Pfizer’s Science and Technology Committee.

Renowned for his banking skills and philanthropy, Blaylock advised on over $150 billion worth of transactions in 2005. He was named one of the Most Powerful Blacks on Wall Street by Black Enterprise Magazine and has sat on the Board of Trustees of Carnegie Hall, NYU, the Inner-City Scholarship Fund and on Prep for Prep, which helps gifted children attain scholarships to attend private schools.

Coincidentally, the only other Pfizer insider to have bought shares in the past nine years also serves on Pfizer’s Science and Technology Committee.

Former U.S. Food and Drug Administration (FDA) Commissioner Dr Scott Gottlieb
, 48, is a Special Partner with venture capital firm New Enterprise Associates (NEA), and is a shrewd operator, like Mr Blaylock.

When he joined the Pfizer board last year, Dr Gottlieb spent $104,160 buying 3,000 shares, and in January 2020, he bought a further 1,000 shares spending $37,000, giving a very positive indication that change is afoot.

No other insiders have bought Pfizer shares since 2011, and that’s why The Edge (the global leader for activist ideas, special situations and Spinoffs) believe both men are betting on a huge surge in Pfizer’s stock price and that potential investors would be wise to make a move now.

Not simply because of Pfizer’s attempts to have a coronavirus vaccine in circulation by October, which could see the share price rocket (giving investors huge returns), but also because Pfizer has a sensational track record in Spinoffs.
Take Zoetis ZTS +0.2%, the world's largest producer of medicine and vaccinations for animals, which Spun in 2013. Investors have had stellar returns with +289% yields, beating the S&P’s +16% return in the same period.


Viatris Spinoff

In July 2019, Pfizer announced a merger between Mylan and Upjohn, the off-patent branded and generic established medicines business, creating a new global pharmaceutical company. The new company was named Viatris in November 2019, with access to 165 markets. In April 2020, it won antitrust clearance from the European Commission.

Pfizer shareholders will receive shares in Viatris, and it should generate annual revenue of between $19 billion and $20 billion with free cash flow of more than $4 billion.


Deriving its name from Latin, the company says Viatris embodies the goal of providing a path—"VIA"—to three—"TRIS"—core goals: expanding access to medicines, leading by innovating to meet patient needs, and being a trusted partner for the healthcare community worldwide.

"We wanted a name that would differentiate our new company and clearly explain how we will be a champion for global health," said Robert J. Coury, who will serve as Executive Chairman.

"We are creating a company unlike any other – a company focused on building a more hopeful and sustainable healthcare journey, empowering patients to live healthier at every stage of life.”

Cerevel Therapeutics — Nasdaq IPO

In addition to the $195bn Viatris Spinoff which has been brewing since July 2019, 171 year-old Pfizer is also involved in the Boston-based Cerevel Therapeutics Nasdaq IPO.

The neuroscience juggernaut was created to specifically treat disorders of the central nervous system, including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction.

Pfizer (which owns a 25% stake in the company) and Bain Capital, who committed $350 million in private equity for a 75% stake, established the company in October 2018.

On July 30, 2020, it was announced that Cerevel Therapeutics was merging with a “public special purpose acquisition company” (SPAC) called Arya Sciences Acquisition Corp II.

Once the deal is complete, Cerevel Therapeutics Holdings will trade on the Nasdaq under the ticker symbol “CERE” by Q4 2020.

In an interview with Fierce Biotech,CEO Tony Coles, M.D. said, “We had been planning a more traditional route to market of a series B/crossover round, and then an IPO later in the fall.

“The lead investor of the series B happened to be Perceptive Advisors, who were also the sponsors for Arya II, the SPAC. In a strategic conversation with them, we started thinking seriously about trying to do in one step what takes most companies two steps to do.”

He added that Cerevel would “inherit a very strong, high-quality shareholder base as a result of the investors in the SPAC. “It’s a group of dream investors any biotech company would want to have,” he added. By the end of the year, Cerevel expects to have $445 million to invest in its growth.

Operation Warp Speed — Covid 19 Vaccine Response

As part of Operation Warp Speed, the U.S. Government has a goal to begin delivering 300 million doses of a vaccine for Covid-19 in 2021. They have placed an initial order with Pfizer and its partner BioNTech of 100 million doses for $1.95 billion and can acquire up to 500 million additional doses.

The U.S. Government will pay the companies $1.95 billion upon the receipt of the first 100 million doses, following FDA authorization or approval. The government also can acquire up to an additional 500 million doses.

Americans will receive the vaccine for free consistent with U.S. government’s commitment for free access for COVID-19 vaccines. “We’ve been committed to making the impossible possible by working tirelessly to develop and produce in record time a safe and effective vaccine to help bring an end to this global health crisis,” said Dr. Albert Bourla, Pfizer Chairman and CEO.

“We made the early decision to begin clinical work and large-scale manufacturing at our own risk to ensure that product would be available immediately if our clinical trials prove successful and an Emergency Use Authorization is granted. We are honored to be a part of this effort to provide Americans access to protection from this deadly virus.”

“Expanding Operation Warp Speed’s diverse portfolio by adding a vaccine from Pfizer and BioNTech increases the odds that we will have a safe, effective vaccine as soon as the end of this year,” said U.S. Department of Health and Human Services Secretary Alex Azar. “Depending on success in clinical trials, today’s agreement will enable the delivery of approximately 100 million doses of this vaccine to the American people.”

With news the Trump administration is considering fast-tracking an experimental coronavirus vaccine from the UK for use in America ahead of the presidential election, the race is heating up.

According to the FT, the US Food and Drug Administration could award “emergency use authorization” (EUA) in October to a vaccine being developed in a partnership between AstraZeneca and Oxford University.

This opens the door to Pfizer, which is also trialing vaccines and is planning to enroll 30,000 participants in Phase III studies they started in July.

The Edge believes there’s at least three good reasons for investors to be confident in Pfizer going forward to 2021, just as insiders Mr Blaylock and Dr Gottlieb are. With Pfizer’s Spinoff of Zoetis providing an outstanding +289% return since 2013, it’s more than certainly proved capable of providing winners to investors.
BioCocktail liked last!

Gebruikersavatar
Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1533
Lid geworden op: 17 sep 2014 14:20
waarderingen: 649
Contacteer:

Re: Pfizer

Bericht door Munnybunny »

Pfizer Inc. Dba Pfizer was awarded a new government contract "65--Manufacture/Distributor Br-Philadelp", total contract value: $48,683,160.88

Gebruikersavatar
Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1533
Lid geworden op: 17 sep 2014 14:20
waarderingen: 649
Contacteer:

Re: Pfizer

Bericht door Munnybunny »

Moderna and Pfizer’s COVID-19 vaccine candidates require ultra-low temperatures, raising questions about storage, distribution
Published: Aug. 31, 2020 at 6:56 a.m. ET
By Jaimy Lee

The storage requirements for mRNA vaccines for COVID-19 ‘would make traditional office or pharmacy administration very difficult,’ one Wall Street analyst said

https://www.marketwatch.com/story/moder ... Sq6ZZ5c16d

Gebruikersavatar
Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1533
Lid geworden op: 17 sep 2014 14:20
waarderingen: 649
Contacteer:

Re: Pfizer

Bericht door Munnybunny »

Pfizer Has Been a Mediocre Stock at Best. Here's Why You Should Consider Buying It Anyway
Good news could be on the way.

Keith Speights
Keith Speights
(TMFFishBiz)
Sep 2, 2020 at 6:09AM
Author Bio
The booming stock market recently hit an all-time high. Many stocks regained all of their losses from earlier in the year and skyrocketed a lot higher. But Pfizer (NYSE:PFE) isn't one of them.

Shares of the big drugmaker are still down close to 5% year to date. That's a lot better than where Pfizer stock was in March, but 2020 so far is yet another dismal year. In 2019, Pfizer's shares fell 10% while the S&P 500 index soared nearly 29%.

No investor likes mediocrity. And let's face it: Pfizer has been a mediocre stock at best. But here's why you should consider buying the big pharma stock anyway.

Say goodbye to Upjohn and hello to stronger growth

What's the primary source for Pfizer's malaise? All you have to do is look at the company's second-quarter results.

Pfizer reported a 3% year-over-year organic revenue decline in Q2. This slide stemmed mainly from the Upjohn unit, which saw sales plunge 31% from the prior-year period. The loss of patent exclusivity for Lyrica was the major culprit. The good news for Pfizer is that it will soon say goodbye to Upjohn and hello to stronger growth.

Keep in mind that Pfizer's biopharma segment posted 6% year-over-year sales growth in the second quarter. And that's with the COVID-19 pandemic disrupting the company's business, especially in the U.S. market.

Pfizer CEO Albert Bourla stated in the company's Q2 conference call that the company remains confident that it will be able to deliver annual revenue growth of at least 6% through 2025 after it spins off Upjohn and merges the unit with Mylan. This transaction is still on track to close in the fourth quarter of 2020.

The big drugmaker should also be able to achieve average annual earnings growth roughly in line with its projected revenue growth. Granted, 6% earnings growth might not seem all that exciting. But it should be enough to close to the middle of the pack in the S&P 500.

Pfizer isn't in the middle of the pack, though, when it comes to dividends. The company is in the top quintile of S&P 500 stocks ranked on dividend yield. Its position shouldn't slip too much after the Upjohn-Mylan deal wraps up. Increased revenue and earnings growth combined with a strong dividend should make Pfizer stock more appealing than it's been in quite a while.

Near-term catalysts on the way
None of this is a secret. But what Pfizer needs to wake investors up to its soon-to-improve fortunes is a positive catalyst or two. The good news is that the company should have some catalysts on the way in the near term.

Pfizer plans to file for FDA approval in the third quarter for abrocitinib in treating atopic dermatitis. Abrocitinib's performance in phase 3 testing shows that it could be more effective than Regeneron's and Sanofi's blockbuster drug Dupixent.

It seems likely that Pfizer could provide more good news related to its pipeline at the investor presentations scheduled for Sept. 14 and 15. But the biggest potential catalyst is the possibility of winning FDA emergency use authorization before the end of the year for BNT162b2, the COVID-19 vaccine candidate developed by Pfizer and BioNTech.

Pfizer and BioNTech recently announced that they have enrolled over half of the targeted 30,000 patients for late-stage testing of BNT162b2. Bourla has publicly stated that he anticipates filing for FDA approval of the vaccine as early as October of this year.

Making mediocrity a memory
The fourth quarter of 2020 should be incredibly important for Pfizer. There's the Upjohn-Mylan close scheduled to wrap up. The potential filing for approval of BNT162b2 could be right around the corner.

But Pfizer doesn't have to win FDA approval of the vaccine to open the door for a huge amount of money to flow in: Its $1.95 billion supply deal with the U.S. government requires only emergency use authorization (EUA) from the FDA. That EUA could be on the way within the next three months.

There could be plenty of good news in store for Pfizer soon. And the company just might be able to make its current mediocrity only a memory.

Gebruikersavatar
Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1533
Lid geworden op: 17 sep 2014 14:20
waarderingen: 649
Contacteer:

Re: Pfizer

Bericht door Munnybunny »

Trump heeft vandaag met PFE gesproken.

...’expects "very good news" on vaccine, therapeutics soon’.

https://youtu.be/0Y2cGbKsPf4

Gebruikersavatar
Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1533
Lid geworden op: 17 sep 2014 14:20
waarderingen: 649
Contacteer:

Re: Pfizer

Bericht door Munnybunny »

BioNTech, Pfizer begin German part of COVID-19 vaccine study
Reuters

FRANKFURT (Reuters) - Biotech firm BioNTech said on Monday it widened an ongoing pivotal global study of its COVID-19 vaccine candidate to include testing in its home country of Germany.

Germany's vaccines regulator, the Paul Ehrlich Institute, gave the approval for the Phase 2/3 trial of the experimental vaccine known as BNT162b2, BioNTech and its partner Pfizer said in a statement.

The global trial was initiated in July, with a view to including about 120 sites globally and seeking up to 30,000 participants in total.

More than 25,000 participants have been enrolled, BioNTech said, adding it remained on track to seek approval for BNT162b2 as early as next month.

Deelnemen aan het forum + meer functies?

Discussieer met duizenden beleggers, minder
advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen 1 minuut!


Plaats reactie